News

Mr. Veitch brings extensive commercial knowledge of the European Union across marketing, sales, market access and general management and has over 24 years of pharmaceutical industry experience.

This new branding reflects the company's increasing commercialization of products and services developed for its proprietary clinical tissue processing methodologies.

Current Pharmaceutical Biotechnology has published up-to-date reviews from more than 25 internationally renowned TGF-ß experts.

Scientists at the Salk Institute for Biological Studies have identified a gene that tells cells to develop multiple cilia, tiny hair-like structures that move fluids through the lungs and brain. Discovery may lead to new ways to replace damaged lung tissues.

The company reported the successful completion of its 28-day rat toxicology. Results demonstrated an ample margin of safety with the dosing planned for the first-in-human study.

Partnership includes US profit share and co-promotion option for Epizyme. The strategic alliance in March 2011 aimed to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients.

Oral treatment can increase patient compliance in the estimated $15 billion US market. The company has filed a provisional patent application for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.

The companies will develop novel drug candidates against multiple targets across different therapeutic areas.

Transaction creates new Nanohale subsidiary named Formycon GmbH.

The partners announced the selection of several novel agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.